AFP and hepatocellular carcinoma: Given the increased risk of HCC due to the use of immunosuppressants in a post-OLT population, it is important to consider HCC screening for all recipients of HBV-positive allografts with liver imaging (e.g., ultrasound, computed tomography, or magnetic resonance imaging) and alpha-fetoprotein (AFP) every six months.